A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Brief description of study

The main purpose of this study is to determine the safet and tolerability of cemiplimab. Cemiplimab-rwic is only approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic cutaneous squamous celi carcinoma (CSCC) or locaiiy advanced CSCC who are not candidates for curative surgery or curative radiation • Side effects that may be experienced by peopie taking cemiplimab • How cemiplimab works in the body • How much cemiplimab is present in your blood • To see effect of cemiplimab on your tumor


Clinical Study Identifier: s19-01357
ClinicalTrials.gov Identifier: NCT03889912
Principal Investigator: John A. Carucci.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.